Close

Deutsche Bank Sees Chelsea Therapeutics (CHTP) Risk Skewed to the Downside ahead of Northera Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. PI
9. NOW
10. CNMD


Go back to Deutsche Bank Sees Chelsea Therapeutics (CHTP) Risk Skewed to the Downside ahead of Northera Approval

Chelsea Therapeutics (CHTP) Has 20-100% Net Upside, Wedbush Said

January 15, 2014 8:38 AM EST

Wedbush analyst Liana Moussatos, Ph.D. reiterated an Outperform rating and $8 fair value target on Chelsea Therapeutics (NASDAQ: CHTP) after an FDA AdCom voted 16 to 1 in favor of approving Northera.

Despite the negative FDA tone in the briefing documents, the voting members favored approval with 16 voting yes, 1 voting no, 0 abstentions, and 0 non-votes," Moussatos highlights. For comparison, the previous FDA panel held in February 2012 also voted for approval with 7 voting yes, 4 voting no, 1 abstention, and 1 non-vote. They note that there were eight panel members who participated in both meetings, and of those, 3... More

Chelsea Therapeutics (CHTP) Target Lifted to $8 at Needham & Company on FDA AdCom Support

January 15, 2014 7:20 AM EST

Needham & Company analyst Alan Carr, Ph.D reiterated a Buy rating and doubled his price target on Chelsea Therapeutics (NASDAQ: CHTP) from $4 to $8 after an FDA AdCom yesterday voted 16-1 in favor of approval of Northera for the treatment of NOH.

Carr notes this is the... More

FDA CRDAC Committee Recommends Approval of Chelsea Therapeutics' (CHTP) NORTHERA

January 14, 2014 4:46 PM EST

(Updated - January 14, 2014 5:13 PM EST)

Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) announced that the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16-1 to recommend approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in... More